Earth Science Tech (ETST) Cash from Financing Activities (2011 - 2026)
Earth Science Tech's (ETST) quarterly Cash from Financing Activities came in at -$44047.0 in Q1 2026, up 95.47% YoY from -$22533.8 in Q1 2025, and up 76.89% on a QoQ basis from -$190608.0 in Q4 2025.
Earth Science Tech (ETST) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Earth Science Tech (ETST) has 15 years of Cash from Financing Activities data on file, last reported at -$44047.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 95.47% year-over-year to -$44047.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$712917.0 (up 58.44% YoY) and the FY2026 annual result came in at -$712917.0, up 58.44% from the prior year.
- Cash from Financing Activities improved to -$44047.0 in Q1 2026, from -$190608.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $350068.0 in Q1 2023 to a low of -$972595.0 in Q1 2025.
- A 5-year average of -$105574.6 and a median of -$86017.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 3065.0% — and 2024, when it sank 795.24%.
- Tracing ETST's Cash from Financing Activities over 5 years: stood at $316500.0 in 2022, then slumped by 150.96% to -$161302.0 in 2023, then jumped by 218.97% to $191894.0 in 2024, then slumped by 199.33% to -$190608.0 in 2025, then jumped by 76.89% to -$44047.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$44047.0 (Q1 2026), -$190608.0 (Q4 2025), and -$211459.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Earth Science Tech | 34.80 Mn | 31.98 Mn | 6.28 Mn | -392,191.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -392,191.00 |
| Jun 30, 2026 | -392,191.00 |
| Mar 31, 2026 | -44,047.00 |
| Mar 31, 2026 | -44,047.00 |
| Dec 31, 2025 | -190,608.00 |
| Dec 31, 2025 | -190,608.00 |
| Sep 30, 2025 | -211,459.00 |
| Sep 30, 2025 | -211,459.00 |
| Jun 30, 2025 | -266,803.00 |
| Jun 30, 2025 | -266,803.00 |
| Mar 31, 2025 | -972,595.00 |
| Mar 31, 2025 | -972,595.00 |
| Dec 31, 2024 | 191,894.00 |
| Dec 31, 2024 | 191,894.00 |
| Sep 30, 2024 | -770,058.00 |
| Sep 30, 2024 | -770,058.00 |
| Jun 30, 2024 | -164,774.00 |
| Jun 30, 2024 | -164,774.00 |
| Mar 31, 2024 | -380,568.00 |
| Mar 31, 2024 | -380,568.00 |